Natco Pharma is currently trading at Rs. 454.50, up by 1.00 points or 0.22% from its previous closing of Rs. 453.50 on the BSE.
The scrip opened at Rs. 455.10 and has touched a high and low of Rs. 461.80 and Rs. 453.00 respectively. So far 3835 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 505.20 on 20-Dec-2012 and a 52 week low of Rs. 330.80 on 03-Jul-2012.
Last one week high and low of the scrip stood at Rs. 469.20 and Rs. 436.00 respectively. The current market cap of the company is Rs. 1421.98 crore.
The promoters holding in the company stood at 56.67% while Institutions and Non-Institutions held 19.30% and 24.04% respectively.
Natco Pharma has received marketing approval for its Rizatriptan Benzoate (Maxalt-MLD) orally disintegrating tablets, 5 mg and 10 mg (base) from US Food & Drug Administration (USFDA). The Company has already commenced shipments of the product, which is being launched by its marketing partner - Breckenridge Pharmaceuticals.
Rizatriptan is used to treat migraine headaches with or without aura (warning signs that occur prior to the onset of a migraine headache). The company is estimating the market to be around $250 million (before generic launch - as of December, 2012).
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: